A Comparative, Randomized, Single-Dose, 2-Way Crossover Pharmacokinetic Comparability Study of CB-839 Administered as Capsule and Tablet Formulations in Healthy Adult Subjects
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Telaglenastat (Primary) ; Telaglenastat (Primary)
- Indications Haematological malignancies; Leukaemia; Malignant melanoma; Non-small cell lung cancer; Renal cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Calithera Biosciences
- 03 Jan 2017 Status changed from not yet recruiting to completed.
- 27 Oct 2016 New trial record